Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|July 22, 2026

The BioPharm Brief: Reduction, Reach, and Reinforcement

Listen
0:00 / 0:00

Arrowhead's plozasiran cut triglycerides up to 81% and pancreatitis events up to 100% in phase 3 trials, Greenwich LifeSciences expanded its GP2 breast cancer vaccine trial into the UK, and Ipsen completed its acquisition of Memo Therapeutics to add the first-in-class antibody potravitug to its rare disease pipeline.

Welcome to the BioPharm Brief, your daily snapshot of the developments shaping the biopharmaceutical industry.

Reduction, reach, and reinforcement mark this week's biologics news, as an RNA interference therapy delivers sharp reductions in a dangerous lipid disorder, a peptide vaccine trial extends its reach into the UK, and a major acquisition reinforces one company's rare disease pipeline.

We'll start with Arrowhead Pharmaceuticals, where phase 3 results for plozasiran, an RNA interference therapy, showed the drug cut triglycerides by up to eighty-one percent in patients with severe hypertriglyceridemia. In the trial's highest-risk patients, those with the most dangerous triglyceride levels and a prior history of pancreatitis, plozasiran reduced pancreatitis events by one hundred percent compared to placebo. The therapy works by suppressing the liver's production of a protein that raises triglyceride levels, and Arrowhead plans to use these results to support a regulatory filing before the end of the year.

Next, Greenwich LifeSciences has expanded its Phase III FLAMINGO-01 trial into the United Kingdom. The trial is evaluating GP2, a peptide vaccine designed to prevent breast cancer recurrence in patients with HER2-expressing tumors. The expansion adds up to ten new UK sites through a collaboration with The Royal Marsden, building on a string of recent regulatory wins that have accelerated enrollment across the trial's global site network.

Finally, Ipsen has completed its acquisition of Memo Therapeutics, adding potravitug, a first-in-class antibody, to its rare disease pipeline. Potravitug targets BK polyomavirus, a common virus that can reactivate in kidney transplant recipients and threaten graft survival. In a Phase 2 trial, patients treated with potravitug were more likely to clear the virus and less likely to develop virus-associated kidney damage, with no approved targeted therapy currently available for this condition.

These three stories capture a full spectrum of biopharma progress, from a therapy delivering dramatic clinical reductions, to a trial reaching more patients, to a company reinforcing its future pipeline.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • Plozasiran cut triglycerides up to 81% and reduced pancreatitis events up to 100% in high-risk patients in Phase 3 trials, positioning Arrowhead for a regulatory filing by year-end.
  • Greenwich LifeSciences expanded its FLAMINGO-01 trial of the GP2 breast cancer vaccine into the UK, adding new sites through a partnership with The Royal Marsden.
  • Ipsen completed its acquisition of Memo Therapeutics, adding the first-in-class antibody potravitug to its rare disease pipeline for kidney transplant patients facing BK virus reactivation.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more